IL123563A - Pharmaceutical formulations comprising amoxycillin and clavulanate in a weight ratio between 14:1 and 16:1 inclusive - Google Patents

Pharmaceutical formulations comprising amoxycillin and clavulanate in a weight ratio between 14:1 and 16:1 inclusive

Info

Publication number: IL123563A
Authority: IL; Israel
Prior art keywords: amoxycillin; clavulanate; formulation; ratio; inclusive
Prior art date: 1995-09-07

Application number

IL12356396A

Other languages

English (en)

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-09-07

Filing date

1996-09-05

Publication date

2002-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21705455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL123563(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-09-05 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2002-02-10 Publication of IL123563A publication Critical patent/IL123563A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

IL12356396A 1995-09-07 1996-09-05 Pharmaceutical formulations comprising amoxycillin and clavulanate in a weight ratio between 14:1 and 16:1 inclusive IL123563A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US335395P	1995-09-07	1995-09-07
PCT/US1996/014554 WO1997009042A1 (en)	1995-09-07	1996-09-05	Pharmaceutical formulation

Publications (1)

Publication Number	Publication Date
IL123563A true IL123563A (en)	2002-02-10

Family

ID=21705455

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12356396A IL123563A (en)	1995-09-07	1996-09-05	Pharmaceutical formulations comprising amoxycillin and clavulanate in a weight ratio between 14:1 and 16:1 inclusive

Country Status (28)

Country	Link
US (3)	US6726908B2 (pt)
EP (3)	EP1093812A3 (pt)
JP (1)	JP3501289B2 (pt)
KR (1)	KR100495585B1 (pt)
CN (1)	CN1289084C (pt)
AR (1)	AR004510A1 (pt)
AT (1)	ATE208618T1 (pt)
AU (1)	AU711441B2 (pt)
BR (1)	BR9610396A (pt)
CA (1)	CA2231194C (pt)
CO (1)	CO4750658A1 (pt)
CY (1)	CY2359B1 (pt)
CZ (1)	CZ299595B6 (pt)
DE (1)	DE69617036T2 (pt)
DK (1)	DK0862431T3 (pt)
ES (1)	ES2165997T3 (pt)
HK (2)	HK1015701A1 (pt)
HU (1)	HUP9901437A3 (pt)
IL (1)	IL123563A (pt)
NO (1)	NO314831B1 (pt)
NZ (3)	NZ318282A (pt)
PL (1)	PL325411A1 (pt)
PT (1)	PT862431E (pt)
SI (1)	SI0862431T1 (pt)
TR (1)	TR199800415T1 (pt)
TW (1)	TW501926B (pt)
WO (1)	WO1997009042A1 (pt)
ZA (1)	ZA967546B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030109503A1 (en) *	1995-06-06	2003-06-12	Smithkline Beecham P.L.C.	Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
TR199800415T1 (en) *	1995-09-07	1998-05-21	Smithkline Beecham Corporation	Farmas�tik form�lasyon.
GB9617780D0 (en) *	1996-08-24	1996-10-02	Smithkline Beecham Plc	Method of treatment
US6294199B1 (en) *	1999-04-13	2001-09-25	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising administering amoxycillin
SE0001330L (sv) *	1999-04-13	2000-10-14	Beecham Pharm Pte Ltd	Novel method of treatment
US7250176B1 (en) *	1999-04-13	2007-07-31	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection
US6878386B1 (en)	1999-04-13	2005-04-12	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
GB2365337A (en) *	1999-04-13	2002-02-20	Beecham Pharma	Amoxycillin and potassium clavulanate high dosage regimen
AU5241200A (en) *	1999-06-29	2001-01-31	Miciopharma Chemical Aktiengesellschaft	Retard formulation of amoxicillin for oral administration
US6955821B2 (en)	2000-04-28	2005-10-18	Adams Laboratories, Inc.	Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en)	2000-04-28	2011-09-06	Reckitt Benckiser Inc.	Sustained release of guaifenesin combination drugs
US7838032B2 (en)	2000-04-28	2010-11-23	Reckitt Benckiser Inc.	Sustained release of guaifenesin
US7985420B2 (en)	2000-04-28	2011-07-26	Reckitt Benckiser Inc.	Sustained release of guaifenesin combination drugs
EP1330236A2 (en)	2000-10-12	2003-07-30	Beecham Pharmaceuticals (Pte) Limited	Formulation containing amoxicillin
US6756057B2 (en)	2000-10-12	2004-06-29	Beecham Pharmaceuticals (Pte) Limited	Amoxicillin and potassium clavulanate dosage form
DE60325709D1 (de)	2002-04-09	2009-02-26	Flamel Tech Sa	Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
KR100456833B1 (ko) *	2002-08-01	2004-11-10	주식회사 대웅	아목시실린 및 클라불라네이트를 함유하는 유핵정
TR200909787A2 (tr)	2009-12-25	2011-07-21	Bi̇lgi̇ç Mahmut	Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
US8614315B2 (en)	2009-12-25	2013-12-24	Mahmut Bilgic	Cefdinir and cefixime formulations and uses thereof
TR201000688A2 (tr)	2010-01-29	2011-08-22	B�Lg�� Mahmut	Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
TR201000687A1 (tr)	2010-01-29	2011-08-22	Bi̇lgi̇ç Mahmut	Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201000686A1 (tr)	2010-01-29	2011-08-22	B�Lg�� Mahmut	Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
WO2013057569A2 (en)	2011-10-19	2013-04-25	Micro Labs Limited	Extended release pharmaceutical composition containing amoxicillin and clavulanic acid
KR20140117523A (ko) *	2012-01-10	2014-10-07	마이클 스펙터	아목시실린 및 클라불란산 칼륨의 소아용 경구 현탁 제형 및 이를 사용하기 위한 방법
WO2013173803A2 (en) *	2012-05-17	2013-11-21	Michael Spector	Formulations of amoxicillin and clavulanate potassium and methods for using same
WO2013173808A2 (en) *	2012-05-17	2013-11-21	Michael Spector	Methods for use of lower dose compositions of amoxicillin and clavulanate potassium and devices for use
EP3364955B1 (en)	2015-10-09	2022-04-20	RB Health (US) LLC	Pharmaceutical formulation

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE41109B1 (en) *	1974-04-20	1979-10-24	Beecham Group Ltd	Novel -lactam antibiotic from streptomyces clavuligerus
JO984B1 (en) *	1977-10-11	1979-12-01	بيتشام غروب ليمتد	A dry pharmaceutical compound with a suitable dosage unit for oral administration
IL58461A0 (en)	1978-10-27	1980-01-31	Beecham Group Ltd	Intramammary compositions comprising a clavulanic acid salt
NZ198241A (en) *	1980-09-27	1983-12-16	Beecham Group Ltd	Tablet containing amoxycillin and potassium clavulanate
EP0080862B1 (en) *	1981-12-02	1985-09-25	Beecham Group Plc	Pharmaceutical formulation comprising beta-lactam antibiotics
US4673637A (en)	1984-04-23	1987-06-16	Hyman Edward S	Method for detecting bacteria in urine and for treating rheumatoid arthritis, essential hypertension and other diseases associated with bacteriuria
DE3887179T2 (de)	1987-03-02	1994-06-16	Brocades Pharma Bv	Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
US5114929A (en) *	1989-03-21	1992-05-19	Beecham Group P.L.C.	Pharmaceutical formulation
GB8909793D0 (en)	1989-04-28	1989-06-14	Beecham Group Plc	Pharmaceutical formulation
KR910009271B1 (ko)	1989-06-20	1991-11-08	김영설	1,1-디옥소페닐실라노일 옥시메틸 D-6-[α-(메틸렌아미노)페닐-아세트아미도]-페니실라네이트와 그의 파라-톨루엔술폰산염
GB9007945D0 (en) *	1990-04-07	1990-06-06	Beecham Group Plc	Pharmaceutical formulation
US5814337A (en) *	1992-10-07	1998-09-29	Beecham Group Plc	Pharmaceutical formulation
GB9109862D0 (en)	1991-05-08	1991-07-03	Beecham Lab Sa	Pharmaceutical formulations
GB9114950D0 (en)	1991-07-11	1991-08-28	Smithkline Beecham Plc	Pharmaceutical formulation
EP0680322B1 (en) *	1993-01-22	2000-07-05	Smithkline Beecham Plc	Use of clavulanate and an antibacterial compound for the treatment of infections
GB9311030D0 (en)	1993-05-28	1993-07-14	Smithkline Beecham Corp	Pharmaceutical formulations
IL109770A0 (en) *	1993-05-29	1994-11-28	Smithkline Beecham Corp	Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9405856D0 (en)	1994-03-24	1994-05-11	Smithkline Beecham Plc	Pharmaceutical formulation
GB9407386D0 (en)	1994-04-14	1994-06-08	Smithkline Beecham Plc	Pharmaceutical formulation
GB9408117D0 (en)	1994-04-23	1994-06-15	Smithkline Beecham Corp	Pharmaceutical formulations
ITMI941169A1 (it)	1994-06-06	1995-12-06	Smithkline Beecham Farma	Formulazioni farmaceutiche
US5567439A (en)	1994-06-14	1996-10-22	Fuisz Technologies Ltd.	Delivery of controlled-release systems(s)
GB9416599D0 (en)	1994-08-17	1994-10-12	Smithkline Beecham Plc	Pharmaceutical formulation
GB9416600D0 (en)	1994-08-17	1994-10-12	Smithkline Beecham Plc	Pharmaceutical formulation
DZ1926A1 (fr)	1994-09-03	2002-02-17	Smithkline Beckman P L C	Formulations pharmaceutiques.
DZ2028A1 (fr)	1995-05-03	2002-10-23	Smithkline Beecham Plc	Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
US5830073A (en)	1995-07-28	1998-11-03	Voss; Brian C.	Bowling lane surfaces
TR199800415T1 (en) *	1995-09-07	1998-05-21	Smithkline Beecham Corporation	Farmas�tik form�lasyon.
KR100499812B1 (ko)	1997-02-14	2005-07-08	스미스클라인 비참 코포레이션	아목시실린 및 클라불라네이트를 포함하는 약제학적 제형
SE9700885D0 (sv)	1997-03-12	1997-03-12	Astra Ab	New pharmaceutical formulation
US6428813B1 (en)	1997-03-25	2002-08-06	Takeda Chemical Industries, Ltd.	Gastrointestinal mucosa-adherent pharmaceutical composition
GB9815532D0 (en)	1998-07-17	1998-09-16	Lek Pharmaceutical & Cvhemical	Pharmaceutical suspension formulation
GB9818927D0 (en)	1998-08-28	1998-10-21	Smithkline Beecham Plc	Pharmaceutical formulation
SE0001330L (sv) *	1999-04-13	2000-10-14	Beecham Pharm Pte Ltd	Novel method of treatment

1996
- 1996-09-05 TR TR1998/00415T patent/TR199800415T1/xx unknown
- 1996-09-05 NZ NZ318282A patent/NZ318282A/xx not_active IP Right Cessation
- 1996-09-05 PL PL96325411A patent/PL325411A1/xx unknown
- 1996-09-05 HU HU9901437A patent/HUP9901437A3/hu not_active Application Discontinuation
- 1996-09-05 CZ CZ0068398A patent/CZ299595B6/cs not_active IP Right Cessation
- 1996-09-05 NZ NZ337247A patent/NZ337247A/en not_active IP Right Cessation
- 1996-09-05 SI SI9630410T patent/SI0862431T1/xx unknown
- 1996-09-05 IL IL12356396A patent/IL123563A/en not_active IP Right Cessation
- 1996-09-05 AU AU69733/96A patent/AU711441B2/en not_active Expired
- 1996-09-05 JP JP51146197A patent/JP3501289B2/ja not_active Expired - Lifetime
- 1996-09-05 DK DK96930817T patent/DK0862431T3/da active
- 1996-09-05 BR BR9610396A patent/BR9610396A/pt not_active Application Discontinuation
- 1996-09-05 WO PCT/US1996/014554 patent/WO1997009042A1/en not_active Application Discontinuation
- 1996-09-05 PT PT96930817T patent/PT862431E/pt unknown
- 1996-09-05 AT AT96930817T patent/ATE208618T1/de not_active IP Right Cessation
- 1996-09-05 EP EP00203970A patent/EP1093812A3/en not_active Ceased
- 1996-09-05 EP EP01201824A patent/EP1147771A1/en not_active Ceased
- 1996-09-05 KR KR10-1998-0701743A patent/KR100495585B1/ko not_active IP Right Cessation
- 1996-09-05 AR ARP960104241A patent/AR004510A1/es not_active Application Discontinuation
- 1996-09-05 EP EP96930817A patent/EP0862431B1/en not_active Revoked
- 1996-09-05 CN CNB961978791A patent/CN1289084C/zh not_active Expired - Lifetime
- 1996-09-05 DE DE69617036T patent/DE69617036T2/de not_active Revoked
- 1996-09-05 ES ES96930817T patent/ES2165997T3/es not_active Expired - Lifetime
- 1996-09-05 CA CA002231194A patent/CA2231194C/en not_active Expired - Lifetime
- 1996-09-06 ZA ZA9607546A patent/ZA967546B/xx unknown
- 1996-09-06 CO CO96047585A patent/CO4750658A1/es unknown
- 1996-10-16 TW TW085110884A patent/TW501926B/zh not_active IP Right Cessation
1997
- 1997-10-27 US US08/722,259 patent/US6726908B2/en not_active Expired - Lifetime
1998
- 1998-03-06 NO NO19981008A patent/NO314831B1/no not_active IP Right Cessation
1999
- 1999-03-02 HK HK99100869A patent/HK1015701A1/xx not_active IP Right Cessation
- 1999-03-02 HK HK02102227.9A patent/HK1043042A1/zh unknown
- 1999-08-13 NZ NZ337246A patent/NZ337246A/xx not_active IP Right Cessation
2001
- 2001-02-20 US US09/788,948 patent/US20010038838A1/en not_active Abandoned
2003
- 2003-05-07 CY CY0300039A patent/CY2359B1/xx unknown
- 2003-11-21 US US10/719,211 patent/US20050261267A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2231194C (en)	2004-07-20
AU6973396A (en)	1997-03-27
EP0862431B1 (en)	2001-11-14
NZ337246A (en)	2000-07-28
KR100495585B1 (ko)	2005-09-09
CO4750658A1 (es)	1999-03-31
HK1043042A1 (zh)	2002-09-06
ATE208618T1 (de)	2001-11-15
EP1147771A1 (en)	2001-10-24
EP1093812A3 (en)	2001-06-06
CN1200672A (zh)	1998-12-02
CZ68398A3 (cs)	1998-07-15
HK1015701A1 (en)	1999-10-22
EP0862431A1 (en)	1998-09-09
NZ318282A (en)	2000-01-28
DE69617036T2 (de)	2002-07-11
JPH11512398A (ja)	1999-10-26
CN1289084C (zh)	2006-12-13
AU711441B2 (en)	1999-10-14
ES2165997T3 (es)	2002-04-01
NO981008D0 (no)	1998-03-06
PT862431E (pt)	2002-04-29
JP3501289B2 (ja)	2004-03-02
US6726908B2 (en)	2004-04-27
EP1093812A2 (en)	2001-04-25
ZA967546B (en)	1998-03-06
US20050261267A1 (en)	2005-11-24
DK0862431T3 (da)	2002-03-11
DE69617036D1 (de)	2001-12-20
CZ299595B6 (cs)	2008-09-17
NO314831B1 (no)	2003-06-02
HUP9901437A2 (hu)	1999-09-28
HUP9901437A3 (en)	2000-03-28
US20010038838A1 (en)	2001-11-08
PL325411A1 (en)	1998-07-20
TR199800415T1 (en)	1998-05-21
WO1997009042A1 (en)	1997-03-13
TW501926B (en)	2002-09-11
US20010043926A1 (en)	2001-11-22
NZ337247A (en)	2001-05-25
BR9610396A (pt)	1999-07-06
KR19990044495A (ko)	1999-06-25
CA2231194A1 (en)	1997-03-13
NO981008L (no)	1998-05-06
CY2359B1 (en)	2004-06-04
AR004510A1 (es)	1998-12-16
SI0862431T1 (en)	2002-06-30
MX9801903A (es)	1998-05-31
EP0862431A4 (en)	1999-07-07

Publication	Publication Date	Title
AU711441B2 (en)	1999-10-14	Pharmaceutical formulation
US6214359B1 (en)	2001-04-10	Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant Streptococcus pneumoniae
AP851A (en)	2000-06-15	Composition comprising amoxycillin and clavulanic acid.
EP1138333B1 (en)	2004-02-25	Medicinal compositions for oral use
WO2001045667A2 (en)	2001-06-28	Water-soluble powders for oral solution and use thereof
US20040202714A1 (en)	2004-10-14	Oral pharmaceutical composition
AU4484199A (en)	1999-10-28	Pharmaceutical formulation
US20020099044A1 (en)	2002-07-25	Composition comprising amoxycillin and clavulanic acid
US20050136117A1 (en)	2005-06-23	Pharmaceutical formulations
MXPA98001903A (en)	1998-10-23	Farmaceut formulation
AU2004246811A1 (en)	2004-12-23	Pharmaceutical formulations comprising amoxicillin and clavulanate
MXPA99001807A (en)	1999-09-20	Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant streptococcus pneumonia
CA2220103C (en)	2006-06-20	Composition comprising amoxycillin and clavulanic acid
EP0843552A2 (en)	1998-05-27	Pharmaceutical formulations

Legal Events

Date	Code	Title
2002-11-10	KB	Patent renewed
2006-10-30	KB	Patent renewed
2010-12-30	KB	Patent renewed
2017-03-30	EXP	Patent expired